Workflow
朗华国际集团(08026) - 2019 Q3 - 季度财报
CB GLOBALCB GLOBAL(HK:08026)2019-02-13 08:31

Financial Performance - The Group's revenue for the nine months ended December 31, 2018, was approximately HK$63,727,000, representing an increase of approximately 100.3% compared to the same period of the previous financial year[5]. - The Group's gross profit for the nine months ended December 31, 2018, was approximately HK$4,866,000, a decrease of approximately HK$1,012,000 compared to the same period of the last financial year[5]. - Loss attributable to owners of the Company for the nine months ended December 31, 2018, amounted to approximately HK$13,855,000, compared to a profit of HK$29,852,000 for the same period in 2017[5]. - The Group's loss before tax for the nine months ended December 31, 2018, was HK$13,855,000, compared to a loss of HK$11,924,000 for the same period in 2017[10]. - The company reported a net loss of HK$13,855,000 for the period, compared to a profit of HK$29,852,000 in the previous year[26]. - Total comprehensive expenses for the period amounted to HK$15,837,000, a significant decrease from HK$17,809,000 in the prior year[27]. - The Group's loss for the period from continuing operations for the nine months ended December 31, 2018, was HK$13,855,000, compared to HK$11,929,000 for the same period in 2017[10]. - The basic loss per share from continuing operations for the nine months and three months ended December 31, 2018 was approximately HK$0.0097 and HK$0.0032 respectively, compared to a profit of HK$0.0247 and a loss of HK$0.0033 in the same periods of 2017[128]. Revenue Breakdown - For the nine months ended December 31, 2018, the total revenue was HK$63,727,000, with external sales from the jewellery business at HK$38,555,000, lending business at HK$947,000, and pharmaceutical business at HK$24,225,000[91]. - The revenue from the Jewellery Business increased by approximately HK$19,358,000, from approximately HK$19,197,000 for the nine months ended December 30, 2017, to approximately HK$38,555,000 for the nine months ended December 31, 2018[154]. - The Group's pharmaceutical business revenue rose by approximately HK$14,232,000 from approximately HK$9,993,000 for the nine months ended December 31, 2017, to approximately HK$24,225,000 for the nine months ended December 31, 2018, marking an increase of about 142%[161]. - The revenue from the jewelry business increased from approximately HK$19,197,000 for the nine months ended December 31, 2017, to approximately HK$38,555,000 for the nine months ended December 31, 2018, representing a growth of about 100%[155]. Expenses and Costs - Selling expenses for the nine months ended December 31, 2018, were HK$1,999,000, down from HK$2,744,000 in the previous year[10]. - Administrative expenses for the nine months ended December 31, 2018, were HK$17,179,000, compared to HK$16,171,000 for the same period in 2017[10]. - The cost of sales for the nine months and three months ended December 31, 2018 was approximately HK$58,861,000 and HK$18,043,000 respectively, compared to HK$25,942,000 and HK$6,085,000 in the same periods of 2017[130]. Dividends and Equity - The Board does not recommend the payment of any dividend for the nine months ended December 31, 2018[5]. - As of December 31, 2018, total equity attributable to equity holders of the company was HK$145,096,000[73]. - Total equity as of 31 December 2018 amounted to approximately HK$135,726,000, an increase from HK$87,850,000 as of 31 March 2018[132]. Shareholder Information - Mr. Zhang Chunhua holds 822,319,294 shares, representing 56.67% of the company's issued share capital[166]. - The total number of shares in issue as of December 31, 2018, is 1,450,963,725[169]. - The company granted 18,100,000 shares during the period ending December 31, 2018[187]. Corporate Governance - The company has complied with all provisions of the Corporate Governance Code throughout the review period, except for the appointment of a Chief Executive Officer until May 18, 2018[197]. - The roles of the Chairman and Chief Executive Officer have been separated since May 18, 2018, complying with the Corporate Governance Code[197]. - The Audit Committee, established on March 7, 2000, has reviewed the financial reporting system and internal control procedures of the group[199]. Business Strategy and Operations - The Group intends to focus on mid-end retail products while also increasing sales to high-end corporate customers[153]. - The Group is focusing on strengthening its marketing and channel efforts to increase user base and improve product quality in the future[162]. - The Group plans to expand its jewelry wholesale business by seeking more clients in southern China to broaden sales channels[155].